anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Recent studies highlight the crucial role of the gut microbiome in post-infectious complications, especially in patients recovering from severe COVID-19. Our research aimed to explore the connection between gut microbiome changes and the cytokine profile of patients with post-COVID syndrome. Using 16S rRNA amplicon sequencing, we analyzed the composition of the gut microbiome in 60 COVID-19 patients over the course of one year. We also measured the levels of serum cytokines and chemokines using the Milliplex system. Our results showed that severe SARS-CoV-2 infection cases, especially those complicated by pneumonia, induce a pro-inflammatory microbial milieu with heightened presence of Bacteroides, Faecalibacterium, and Prevotella_9. Furthermore, we found that post-COVID syndrome is characterized by a cross-correlation of various cytokines and chemokines MDC, IL-1b, Fractalkine, TNFa, FGF-2, EGF, IL-1RA, IFN-a2, IL-10, sCD40L, IL-8, Eotaxin, IL-12p40, and MIP-1b as well as a shift in the gut microbiome towards a pro-inflammatory profile. At the functional level, our analysis revealed associations with post-COVID-19 in homolactic fermentation, pentose phosphate, NAD salvage, and flavin biosynthesis. These findings highlight the intricate interplay between the gut microbiota, their metabolites, and systemic cytokines in shaping post-COVID symptoms. Unraveling the gut microbiome's role in post-infectious complications opens avenues for new treatments for those patients with prolonged symptoms.
This randomized controlled intervention study aimed to compare the effects of a Dietary Approaches to Stop Hypertension (DASH) diet and a salt-free diet on blood pressure in hypertension patients. Methods: This study was conducted with 60 patients with primary hypertension. One group (n=30) was given an individualized DASH diet, the other group was given a salt-free diet (n=30), and the participants were followed for two months.
Patients receive NBTXR3 IT on day 1. Patients then undergo IMRT/IMPT QD on days 15-50. Beginning the first day of radiation therapy, patients also receive pembrolizumab IV over 30 minutes on day 1. Cycles repeat every 3 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.
Wound management in obesity is complicated by excessive exudates from wounded areas, pressure ulcerations due to stacking of the fat layer, and vascular rarefaction. The current study explored the development of biomaterials for reprogramming the altered wound microenvironment under obese conditions. Self-assembled collagen biomatrix with trans and de novo browning activator, apigenin, was fabricated as a soft tissue regenerative wound dressing material. The as-synthesized self-assembled collagen biomatrix exhibited excellent thermal, mechanical, and biological stability with a superior wound exudate absorption capacity. The apigenin self-assembled collagen biomatrix exhibited porous 3-D microstructure that mimicked the extracellular matrix that promoted cell adhesion and proliferation. The apigenin self-assembled collagen multifunctional biomatrix triggered adaptive localized thermogenesis in the subcutaneous fat layer, resulting in the activation of angiogenesis and fibroblast spreading and migration. The in vivo wound healing assay performed in DIO-C57BL6 mice showed faster tissue regeneration within 9 days, with well-defined neo-epidermis, blood vessel formation, thick collagen deposition, minimal inflammation, and significant activation of browning in the subcutaneous adipose layer. This study paves the way forward for the development of specialized regenerative biomatrices that reprogram the obese wound bed for faster tissue regeneration.
BACKGROUND AND OBJECTIVES: Suprasellar tumors, particularly pituitary adenomas (PAs), commonly present with visual decline, and the endoscopic endonasal transsphenoidal approach (EETA) is the primary management for optic apparatus decompression. Patients presenting with complete preoperative monocular blindness comprise a high-risk subgroup, given concern for complete blindness. This retrospective cohort study evaluates outcomes after EETA for patients with PA presenting with monocular blindness.
METHODS: Retrospective analysis of all EETA cases at our institution from June 2012 to August 2023 was performed. Inclusion criteria included adults with confirmed PA and complete monocular blindness, defined as no light perception, and a relative afferent pupillary defect secondary to tumor mass effect.
RESULTS: Our cohort includes 15 patients (9 males, 6 females), comprising 2.4% of the overall PA cohort screened. The mean tumor diameter was 3.8 cm, with 6 being giant PAs (>4 cm). The mean duration of preoperative monocular blindness was 568 days. Additional symptoms included contralateral visual field defects (n = 11) and headaches (n = 10). Two patients presented with subacute PA apoplexy. Gross total resection was achieved in 46% of patients, reflecting tumor size and invasiveness. Postoperatively, 2 patients experienced improvement in their effectively blind eye and 2 had improved visual fields of the contralateral eye. Those with improvements were operated within 10 days of presentation, and no patients experienced worsened vision.
CONCLUSION: This is the first series of EETA outcomes in patients with higher-risk PA with monocular blindness on presentation. In these extensive lesions, vision remained stable for most without further decline and improvement from monocular blindness was observed in a small subset of patients with no light perception and relative afferent pupillary defect. Timing from vision loss to surgical intervention seemed to be associated with improvement. From a surgical perspective, caution is warranted to protect remaining vision and we conclude that EETA is safe in the management of these patients.
The recommended dose of CLARINEX Syrup in the pediatric population is based on cross-study comparison of the plasma concentration of CLARINEX in adults and pediatric subjects. The safety of CLARINEX Syrup has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies. Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of CLARINEX are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of CLARINEX Syrup in these age groups is supported by evidence from adequate and well-controlled studies of CLARINEX Tablets in adults. The safety and effectiveness of CLARINEX Tablets or CLARINEX Syrup have not been demonstrated in pediatric patients less than 6 months of age.

The CLARINEX RediTabs Tablet 2.5 mg tablet has not been evaluated in pediatric patients. Bioequivalence of the CLARINEX RediTabs Tablet and the previously marketed RediTabs Tablet was established in adults. In conjunction with the dose finding studies in pediatrics described, the pharmacokinetic data for CLARINEX RediTabs Tablet supports the use of the 2.5 mg dose strength in pediatric patients 6–11 years of age.
Subjects recruited to Cohort I will include patients who are scheduled to undergo oral lesion biopsy as well as patients who are determined to need a biopsy at the time of visual examination, which often occurs in-clinic. Cohort I will consist of 125 oral lesion biopsy patients total. Prior to the start of enrollment in this Cohort, up to 5 additional subjects will be enrolled to optimize the data acquisition process.
PURPOSE: Provided is a device for storing and applying to provide a notable and durable effects by extending or curling keratinous fiber, to be heated without a damage of cosmetic properties even in the event of repeated use, and to be used more conveniently than a conventional device. CONSTITUTION: The storing and applying device includes a container, a composition of make-up and care product, an applying device(10) for applying the composition of make-up and care product, and a heating device(53). The composition of make-up and care product is contained within the container and has a thermal profile having a peak of fusion whose width is lower or equal to 10 deg.C in the middle height. The heating device heats the composition to a temperature greater than the melting point thereof beforehand, simultaneously, or subsequently application of the composition. The temperature is greater than the final melting point of the composition. The heating device is produced as a separate device distinct from the storing and applying device. The storing and applying device is produced in form of a kit.
1467478 Microcapsules FUJI PHOTO FILM CO Ltd 17 July 1974 [17 July 1973] 31764/74 Heading B8C [Also in Division C3] Microcapsules having hydrophobic liquid cores are produced by: (1) emulsifying, in a continuous phase comprising a hydrophilic liquid, a hydrophobic liquid having dissolved therein an organic compound, (ii) introducing into the continuous phase all the ingredients necessary to form a resin, (iii) forming a resin wall about the droplets of emulsified hydrophobic liquid from said ingredients, wherein said organic compound forms a covalent bond with at least one of said ingredients under conditions in which said resin is formed. The ingredients necessary to form a resin are a combination of an amine and an epoxy resin, an amine and an aldehyde, a urea resin and an aldehyde, a urea resin and an amine, a melamine resin and an amine, or a melamine resin and an aldehyde. The ingredients may suitably be a self-polymerizable urea resin or a self-polymerizable melamine resin. The organic compound may be an isocyanate, an amine, an epoxide, an acid chloride, a chloroformate or an aldehyde. The hydrophobic liquid is a natural or synthetic oil. In the examples (1) a solution of a hydrophobic liquid, isopropyl naphthalene, has dissolved therein tolylene diisocyanate, and the resulting solution is emulsified in water, the droplers so formed then being encapsulated in a resin formed by polymerizing formaldehyde with an adduct of acrylonitrile and 3,9-bisaminopropyl - 2,4,8,10 - tetraoxaspiro - [5,5]- undecane, (2) an adduct of trimethylolpropane and hexamethylene diisocyanate is dissolved in a perfume oil as a hydrophobic liquid, the resulting solution is then emulsified in water and the droplets so formed encapsulated in a resin formed by polymerizing polyethylene imine with glyoxal, (3) phthalaldehyde is dissolved in diethyl diphenyl ethane as a hydrophobic liquid, the resulting solution is then emulsified and the droplets encapsulated in a resin formed by polymerizing an epoxy polyurea polyamide co-condensed resin with an adduct of acrylonitrile and 3,9-bis-aminopropyl-2,4,8,10-tetraoxaspiro - [5,5] - undecane, and (4) phenylenediamine is dissolved in toluene as a hydrophobic liquid, the resulting solution is then emulsified and the droplets so formed encapsulated in a resin formed by the polymerization of a melamine-formaldehyde resin.
Adolescence is the only age category where the number of females infected with HIV outnumber the number of males. Despite these data, only three randomized controlled trials have evaluated the efficacy of a gender-specific HIV-risk reduction program for adolescent females. The proposed research aims to address this gap in HIV prevention science, and will evaluate the short and longer-term efficacy of a HIV-prevention intervention for adolescent girls. We will recruit 640 adolescent females aged 15 to 19 years from family planning clinics and randomly assign them to one of two conditions: (a) an HIV-risk reduction intervention based on the Information-Motivation-Behavioral Skills (IMB) model (Fisher \& Fisher, 1992) or (b) a structurally equivalent health promotion control group (CTL) both supplemented by booster sessions at 3 and 6 months. At a short-term (3-month) follow-up, we hypothesize that IMB participants will increase HIV-related knowledge, motivation, and behavioral skills, and decrease the frequency of risky sexual practices relative to CTL participants. We will reassess all participants at 6 and 12 months to evaluate the longer-term efficacy of the interventions. At these longer-term follow-ups, we hypothesize that IMB participants will demonstrate higher levels of HIV knowledge, motivation, and behavioral skills; decreased risky sexual practices; and decreased rates of STDs (Chlamydia, gonorrhea) relative to the CTL participants. The final aim of the proposed research is to determine whether the constructs in the Information-Motivation-Behavioral Skills (IMB) Model (Fisher \& Fisher, 1992), can account for variability in HIV-related behavior. We hypothesize that preventive behavior at 6 and 12 months will be a function of a participant's HIV-related information, motivation, and behavioral skills at the 3-month follow-up, and that information and motivation will be partially mediated by behavioral skills to influence the initiation and maintenance of HIV preventive behavior. The long-term intent of the proposed research is to develop a risk reduction program that can be used by community-based health organizations to reduce the risk of HIV infection among adolescent females.
Insulin glargine (insulin glargine injection) is a sterile solution of insulin glargine for subcutaneous use. Insulin glargine is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent [see Clinical Pharmacology (12)]. Insulin glargine has low aqueous solubility at neutral pH. At pH 4 insulin glargine is completely soluble. After injection into the subcutaneous tissue, the acidic solution is neutralized, leading to formation of microprecipitates from which small amounts of insulin glargine are slowly released, resulting in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile allows once-daily dosing as a basal insulin. Insulin glargine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12) as the production organism. Insulin glargine differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the C-terminus of the B-chain. Chemically, insulin glargine is 21A-Gly-30Ba-L-Arg-30Bb-L-Arg-human insulin and has the empirical formula C267H404N72O78S6 and a molecular weight of 6063. Insulin glargine has the following structural formula:

Insulin glargine consists of insulin glargine dissolved in a clear aqueous fluid. Each milliliter of insulin glargine injection contains 100 units (3.6378 mg) insulin glargine.

The 10 mL vial presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, 20 mcg polysorbate 20, and water for injection.

The 3 mL prefilled pen presentation contains the following inactive ingredients per mL: 30 mcg zinc, 2.7 mg m-cresol, 20 mg glycerol 85%, and water for injection.

The pH is adjusted by addition of aqueous solutions of hydrochloric acid and sodium hydroxide. Insulin glargine has a pH of approximately 4.
The treatment of overdosage with promethazine is essentially symptomatic and supportive. Only in cases of extreme overdosage or individual sensitivity do vital signs including respiration, pulse, blood pressure, temperature and EKG need to be monitored. Activated charcoal orally or by lavage may be given, or sodium or magnesium sulfate orally as a cathartic. Attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. Diazepam may be used to control convulsions. Acidosis and electrolyte losses should be corrected. Note that any of the depressant effects of promethazine are not reversed by naloxone. Avoid analeptics which may cause convulsions.

Severe hypotension usually responds to the administration of norepinephrine or phenylephrine. EPINEPHRINE SHOULD NOT BE USED since its use in patients with partial adrenergic blockade may further lower the blood pressure.

Limited experience with dialysis indicates that it is not helpful.
This study used data from the National Health and Nutrition Examination Survey (NHANES) to investigate the relationship between the triglyceride-glucose (TyG) index and gallstones. We evaluated the data collected between 2017 to 2020. To evaluate the relationship between TyG index and gallstones, logistic regression analysis, basic characteristics of participants, subgroup analysis, and smooth curve fitting were utilized. The study included 3870 participants over the age of 20 years, 403 of whom reported gallstones, with a prevalence rate of 10.4%. After adjusting for all confounding factors, the risk of gallstones increased by 41% for each unit increase in the TyG index (OR 1.41, 95% CI 1.07, 1.86). The smooth curve fitting also showed a positive correlation between the TyG index and gallstones. Subgroup analysis revealed a significant positive relationship between the TyG index and the risk of gallstones in those aged < 50 years, women, individuals with total cholesterol levels > 200 mg/dL, individuals with body mass index (BMI) > 25, and individuals without diabetes. The risk of gallstones is positively correlated with a higher TyG index. Thus, the TyG index can be used as a predictor of the risk of gallstones.
ABSTRACT      A method for stimulating growth in animal or poultry which involves feeding a complete feed to the animal or poultry.  The complete feed contains (i) gentian violet and (ii) the remainder inert ingredients.  The inert ingredients include all of the Inert ingredients normally in a complete or basal animal or poultry feed.  The gentian violet is a growth promoter for animal or poultry.  The gentian violet is present in the feed in an amount between 0.00077 and 0.01 percent by weight, based on the weight of the feed.  The growth of the animal or poultry is increased at a rate significantly faster than if the animal or poultry had not been fed the complete feed containing the gentian violet.  A method for treating or preventing Candida albicans infections in animals and/or poultry.
Methods and devices are provided for the localized administration to a patient of moieties effective for inhibiting unwanted cellular growth, including restenosis of an artery treated with a stent implant for blockage of blood flow by an atherosclerotic lesion. After implantation of a medical device capable of moiety-binding, moieties effective at inhibiting unwanted cellular growth are administered locally to a patient. In this manner the deleterious side-effects of systemic administration of moieties are avoided. Upon localized administration, the moieties bind the medical device, rendering the medical device itself capable of inhibiting unwanted cellular growth. According to an embodiment, after implantation of a stent, radioactive moieties specific for receptors immobilized on the stent surface are locally administered using a balloon perfusion catheter. The moieties bind specifically the receptors, becoming immobilized thereto, thereby rendering the stent radioactive and effective for inhibiting restenosis.
FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to new compounds of the formula (I)   and their pharmaceutically acceptable salts and esters eliciting inhibitory activity with regard to endothelin receptors. Compounds can be used for treatment of diseases associated with anomalous vascular tone and endothelial dysfunction. In compounds of the formula (I) R 1  means pyridyl, thiazolyl optionally substituted with halogen atom, lower alkyl, hydroxy-lower alkyl or lower alkenyl; R 2  means R 21 , -Y-R 22  or aromatic monovalent 5-membered carbocyclic radical comprising at least one heteroatom taken among nitrogen and oxygen atom and this carbocyclic radical can be optionally substituted with lower alkyl; R 21  means cyano-group, hydroxy-lower alkyl, carboxy-group,  , amidino-, hydroxyamidino-group, lower alkoxycarbonyl or hydroxy-lower alkoxycarbonyl; R 22  means hydrogen atom, lower alkanoyl, carboxy-lower alkyl, lower alkoxycarbonyl, lower alkoxycarbonyl-lower alkyl, carbamoyl-lower alkyl, di-lower alkyl-carbamoyl-lower alkyl, allyl, lower alkyl or hydroxy-lower alkyl; R a  means hydrogen atom or lower alkyl optionally substituted with hydroxy-group; R b  means hydrogen atom or lower alkyl; R c  means hydrogen atom, acetyl or lower alkylsulfonyl; X means -CH- or -N-; Y means -O-, -NH-. Invention relates also to pharmaceutical composition eliciting inhibitory capacity with regard to endothelin receptor and comprising compound of the formula (I) and pharmaceutically acceptable carrier and/or adjuvant. EFFECT: valuable medicinal properties of compounds. 13 cl, 5 tbl, 90 ex
An anti-microbial dental impression composition comprises at least one material capable of forming a cured dental impression material, an anti-microbial agent and a wetting agent. The composition may be provided as a kit of parts, wherein the antimicrobial agent and wetting agent are added to one or both parts of a two-part polymerisable material. The dental impression material may comprise silicones, polysulphides, polyethers, polyacrylics or alginates. The anti-microbial agent is preferable a silver-containing substance such as silver benzoate or a silver-containing, sodium calcium phosphate glass. The wetting agent is preferably an anionic wetting agent such as sodium lauryl sulphate. Moulded dental impressions formed from this composition are provided. The wetting agent improves the anti-microbial activity of the anti-microbial agent.
The invention provides a novel acylhydrazone molecular switch, a synthesis method thereof and a method for photoinduced controlled release of a drug. The molecular switch is formed by condensing 2-methoxy naphthaldehyde and benzoyl hydrazine. Because two adjacent sides of the acylhydrazone imine group have groups with large steric hindrance, the E-isomer of the acylhydrazone imine group is easy to be converted into the Z-isomer under illumination, so that the conversion efficiency of the E-Z isomer is up to 99 percent, and the quantum yield is up to 89 percent. After the amphiphilic polymer is prepared into an amphiphilic molecule switch, the amphiphilic polymer can be self-assembled in water to generate nano vesicles, and the vesicles can also be subjected to E-Z isomer conversion with high conversion rate under illumination. The vesicle can contain and load anticancer drug procarbazine, so that the solubility of the drug in water is increased by 225 times. Under the irradiation of light, the included procarbazine can be released from the vesicle.
Alcohol abuse induces various neurological disorders including motor learning deficits, possibly by affecting neuronal and astrocytic activity. Physical exercise is one effective approach to remediate synaptic loss and motor deficits as shown by our previous works. In this study, we unrevealed the role of exercise training in the recovery of cortical neuronal and astrocytic functions. Using a chronic alcohol injection mouse model, we found the hyperreactivity of astrocytes along with dendritic spine loss plus lower neuronal activity in the primary motor cortex. Persistent treadmill exercise training, on the other hand, improved neural spine formation and inhibited reactive astrocytes, alleviating motor learning deficits induced by alcohol exposure. These data collectively support the potency of endurance exercise in the rehabilitation of motor functions under alcohol abuse.